Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 24 | 2023 | 329 | 7.610 |
Why?
|
| Influenza Vaccines | 16 | 2022 | 142 | 5.410 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 15 | 2023 | 80 | 3.340 |
Why?
|
| Vaccination | 10 | 2022 | 254 | 2.280 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 6 | 2023 | 102 | 1.970 |
Why?
|
| Vaccines | 5 | 2022 | 80 | 1.930 |
Why?
|
| Influenza A virus | 4 | 2023 | 169 | 1.820 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 2018 | 113 | 1.660 |
Why?
|
| Host-Pathogen Interactions | 7 | 2020 | 231 | 1.650 |
Why?
|
| Orthomyxoviridae | 7 | 2020 | 37 | 1.630 |
Why?
|
| Pneumococcal Infections | 4 | 2018 | 46 | 1.610 |
Why?
|
| Communicable Diseases | 3 | 2023 | 63 | 1.540 |
Why?
|
| Streptococcus pneumoniae | 4 | 2018 | 48 | 1.500 |
Why?
|
| Antigenic Variation | 5 | 2018 | 26 | 1.470 |
Why?
|
| B-Lymphocytes | 5 | 2019 | 724 | 1.450 |
Why?
|
| Evolution, Molecular | 7 | 2018 | 813 | 1.320 |
Why?
|
| Seasons | 8 | 2020 | 223 | 1.290 |
Why?
|
| Antibodies, Viral | 8 | 2021 | 293 | 1.270 |
Why?
|
| Selection, Genetic | 4 | 2018 | 502 | 1.130 |
Why?
|
| Epidemics | 3 | 2023 | 33 | 1.060 |
Why?
|
| Models, Biological | 7 | 2020 | 1749 | 1.030 |
Why?
|
| Immunologic Memory | 3 | 2021 | 152 | 0.940 |
Why?
|
| Antigens, Viral | 8 | 2021 | 143 | 0.930 |
Why?
|
| Age Distribution | 2 | 2021 | 204 | 0.920 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2021 | 13 | 0.920 |
Why?
|
| Cross Protection | 2 | 2021 | 8 | 0.900 |
Why?
|
| Biological Evolution | 5 | 2021 | 919 | 0.870 |
Why?
|
| Adaptive Immunity | 3 | 2015 | 164 | 0.860 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2020 | 13 | 0.850 |
Why?
|
| Influenza B virus | 2 | 2021 | 29 | 0.840 |
Why?
|
| Models, Theoretical | 4 | 2021 | 482 | 0.820 |
Why?
|
| Models, Immunological | 4 | 2018 | 80 | 0.800 |
Why?
|
| Off-Label Use | 1 | 2021 | 16 | 0.790 |
Why?
|
| Antibodies | 2 | 2023 | 350 | 0.760 |
Why?
|
| Humans | 55 | 2023 | 86643 | 0.720 |
Why?
|
| Silent Mutation | 1 | 2018 | 3 | 0.650 |
Why?
|
| HIV | 1 | 2018 | 46 | 0.640 |
Why?
|
| Disease Susceptibility | 3 | 2020 | 193 | 0.610 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 71 | 0.590 |
Why?
|
| Humidity | 1 | 2017 | 89 | 0.590 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.590 |
Why?
|
| Adaptation, Physiological | 3 | 2018 | 306 | 0.590 |
Why?
|
| Carrier State | 2 | 2018 | 39 | 0.580 |
Why?
|
| Models, Statistical | 8 | 2022 | 574 | 0.580 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 73 | 0.570 |
Why?
|
| Pandemics | 6 | 2022 | 740 | 0.550 |
Why?
|
| Antibody Diversity | 1 | 2015 | 25 | 0.540 |
Why?
|
| Immunodominant Epitopes | 2 | 2015 | 19 | 0.530 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.510 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 21 | 0.490 |
Why?
|
| Hong Kong | 3 | 2023 | 45 | 0.460 |
Why?
|
| Immune System | 1 | 2014 | 93 | 0.460 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 7 | 2021 | 70 | 0.460 |
Why?
|
| Haemophilus Infections | 1 | 2012 | 6 | 0.450 |
Why?
|
| Haemophilus influenzae | 1 | 2012 | 13 | 0.450 |
Why?
|
| Incidence | 5 | 2020 | 1577 | 0.430 |
Why?
|
| Nasopharynx | 1 | 2012 | 47 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 746 | 0.420 |
Why?
|
| Child | 8 | 2022 | 6927 | 0.420 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1195 | 0.410 |
Why?
|
| Antigens, Bacterial | 1 | 2012 | 134 | 0.400 |
Why?
|
| Computer Simulation | 6 | 2022 | 1078 | 0.400 |
Why?
|
| Host Specificity | 1 | 2010 | 10 | 0.380 |
Why?
|
| Eggs | 2 | 2021 | 12 | 0.370 |
Why?
|
| RNA Viruses | 1 | 2008 | 9 | 0.330 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 286 | 0.330 |
Why?
|
| Animals | 13 | 2023 | 26582 | 0.330 |
Why?
|
| Virus Diseases | 1 | 2008 | 97 | 0.310 |
Why?
|
| Child, Preschool | 4 | 2020 | 3612 | 0.310 |
Why?
|
| Age Factors | 3 | 2021 | 1851 | 0.290 |
Why?
|
| Cross Reactions | 3 | 2018 | 106 | 0.280 |
Why?
|
| Pneumococcal Vaccines | 2 | 2018 | 28 | 0.270 |
Why?
|
| Basic Reproduction Number | 2 | 2022 | 6 | 0.250 |
Why?
|
| Zoonoses | 2 | 2016 | 26 | 0.240 |
Why?
|
| Algorithms | 3 | 2018 | 1830 | 0.230 |
Why?
|
| Aged | 8 | 2022 | 18415 | 0.230 |
Why?
|
| Epitopes | 3 | 2021 | 255 | 0.230 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 52 | 0.220 |
Why?
|
| Adult | 9 | 2021 | 25648 | 0.220 |
Why?
|
| Germ Cells | 1 | 2023 | 126 | 0.220 |
Why?
|
| Antibodies, Neutralizing | 3 | 2020 | 112 | 0.220 |
Why?
|
| Cohort Studies | 2 | 2020 | 2767 | 0.220 |
Why?
|
| Young Adult | 5 | 2021 | 5976 | 0.220 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 49 | 0.210 |
Why?
|
| Infant | 3 | 2020 | 3046 | 0.210 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6509 | 0.210 |
Why?
|
| Amino Sugars | 1 | 2021 | 3 | 0.200 |
Why?
|
| Ferrets | 2 | 2018 | 47 | 0.200 |
Why?
|
| New Zealand | 1 | 2021 | 22 | 0.200 |
Why?
|
| Adolescent | 5 | 2021 | 8981 | 0.200 |
Why?
|
| Viral Load | 1 | 2022 | 148 | 0.200 |
Why?
|
| Prevalence | 3 | 2020 | 1239 | 0.200 |
Why?
|
| Mass Vaccination | 1 | 2021 | 8 | 0.200 |
Why?
|
| Health Priorities | 1 | 2021 | 23 | 0.200 |
Why?
|
| Immune Evasion | 1 | 2021 | 33 | 0.200 |
Why?
|
| Phylogeny | 3 | 2018 | 1137 | 0.190 |
Why?
|
| Polysaccharides | 1 | 2021 | 89 | 0.190 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2020 | 46 | 0.190 |
Why?
|
| Time Factors | 3 | 2019 | 5210 | 0.190 |
Why?
|
| Wisconsin | 1 | 2020 | 39 | 0.190 |
Why?
|
| Probability | 1 | 2021 | 355 | 0.190 |
Why?
|
| Immunity, Innate | 2 | 2015 | 409 | 0.190 |
Why?
|
| Models, Genetic | 2 | 2015 | 926 | 0.180 |
Why?
|
| Alleles | 1 | 2023 | 1128 | 0.180 |
Why?
|
| Hemagglutinins | 1 | 2019 | 19 | 0.180 |
Why?
|
| Vaccines, Inactivated | 1 | 2018 | 29 | 0.170 |
Why?
|
| Vaccination Coverage | 1 | 2018 | 5 | 0.170 |
Why?
|
| Computational Biology | 2 | 2020 | 528 | 0.170 |
Why?
|
| Amino Acid Substitution | 2 | 2018 | 339 | 0.160 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 67 | 0.160 |
Why?
|
| Genome, Viral | 1 | 2018 | 74 | 0.160 |
Why?
|
| Plasma Cells | 1 | 2018 | 80 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 865 | 0.160 |
Why?
|
| Sentinel Surveillance | 2 | 2022 | 23 | 0.160 |
Why?
|
| Alphapapillomavirus | 1 | 2017 | 45 | 0.150 |
Why?
|
| New York City | 1 | 2016 | 59 | 0.150 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 549 | 0.150 |
Why?
|
| Chicago | 2 | 2022 | 1379 | 0.140 |
Why?
|
| Phylogeography | 1 | 2016 | 41 | 0.140 |
Why?
|
| Middle Aged | 6 | 2021 | 25028 | 0.140 |
Why?
|
| Genetic Variation | 3 | 2014 | 1351 | 0.140 |
Why?
|
| Clonal Selection, Antigen-Mediated | 1 | 2015 | 8 | 0.140 |
Why?
|
| Temperature | 1 | 2017 | 396 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1805 | 0.130 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 37 | 0.130 |
Why?
|
| Antibody Affinity | 1 | 2015 | 38 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1019 | 0.130 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2015 | 32 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 938 | 0.130 |
Why?
|
| Germinal Center | 1 | 2015 | 55 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 456 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 239 | 0.130 |
Why?
|
| Species Specificity | 2 | 2012 | 678 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1135 | 0.120 |
Why?
|
| Genetics, Population | 1 | 2016 | 394 | 0.120 |
Why?
|
| Microbial Interactions | 1 | 2012 | 9 | 0.110 |
Why?
|
| Mutation | 3 | 2019 | 3968 | 0.110 |
Why?
|
| Genetic Fitness | 1 | 2012 | 37 | 0.110 |
Why?
|
| Serotyping | 1 | 2012 | 28 | 0.110 |
Why?
|
| Mice | 2 | 2023 | 11352 | 0.110 |
Why?
|
| Bacterial Capsules | 1 | 2012 | 28 | 0.110 |
Why?
|
| Population Dynamics | 1 | 2012 | 130 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3640 | 0.100 |
Why?
|
| Measles virus | 1 | 2011 | 14 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 2 | 2022 | 55 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 62 | 0.100 |
Why?
|
| Stochastic Processes | 1 | 2010 | 74 | 0.100 |
Why?
|
| Illinois | 2 | 2022 | 462 | 0.090 |
Why?
|
| Emigration and Immigration | 1 | 2010 | 48 | 0.090 |
Why?
|
| Receptors, Virus | 1 | 2010 | 74 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2011 | 219 | 0.090 |
Why?
|
| Cats | 1 | 2010 | 303 | 0.090 |
Why?
|
| Phenotype | 2 | 2014 | 2378 | 0.090 |
Why?
|
| Chickens | 2 | 2021 | 212 | 0.090 |
Why?
|
| United States | 5 | 2022 | 6672 | 0.090 |
Why?
|
| Birds | 1 | 2010 | 157 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 1014 | 0.080 |
Why?
|
| World Health Organization | 2 | 2021 | 103 | 0.070 |
Why?
|
| Epidemiological Monitoring | 2 | 2016 | 39 | 0.070 |
Why?
|
| Male | 4 | 2020 | 40965 | 0.060 |
Why?
|
| Female | 4 | 2022 | 44532 | 0.060 |
Why?
|
| Asymptomatic Infections | 1 | 2022 | 16 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 94 | 0.050 |
Why?
|
| Computer Systems | 1 | 2022 | 79 | 0.050 |
Why?
|
| Biohazard Release | 1 | 2021 | 1 | 0.050 |
Why?
|
| Philadelphia | 1 | 2020 | 16 | 0.050 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2020 | 37 | 0.050 |
Why?
|
| China | 1 | 2021 | 228 | 0.050 |
Why?
|
| Forecasting | 2 | 2011 | 304 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2020 | 171 | 0.050 |
Why?
|
| Global Health | 2 | 2011 | 193 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 454 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 615 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 80 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 143 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2017 | 77 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 920 | 0.040 |
Why?
|
| Ovum | 1 | 2017 | 58 | 0.040 |
Why?
|
| Glycosylation | 1 | 2017 | 129 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1621 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 456 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 2468 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 849 | 0.040 |
Why?
|
| Virulence Factors | 1 | 2016 | 108 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1376 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2894 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1139 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2013 | 30 | 0.030 |
Why?
|
| Parvovirus, Canine | 1 | 2011 | 1 | 0.030 |
Why?
|
| Disease Vectors | 1 | 2011 | 5 | 0.030 |
Why?
|
| Parvoviridae Infections | 1 | 2011 | 6 | 0.030 |
Why?
|
| Animals, Domestic | 1 | 2011 | 12 | 0.030 |
Why?
|
| Switzerland | 1 | 2011 | 17 | 0.030 |
Why?
|
| Measles | 1 | 2011 | 15 | 0.030 |
Why?
|
| Animals, Wild | 1 | 2011 | 40 | 0.030 |
Why?
|
| Disease Reservoirs | 1 | 2011 | 22 | 0.030 |
Why?
|
| Dogs | 1 | 2011 | 685 | 0.020 |
Why?
|
| Geographic Information Systems | 1 | 2010 | 20 | 0.020 |
Why?
|
| Asia | 1 | 2010 | 95 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2011 | 300 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2261 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 8489 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 966 | 0.020 |
Why?
|
| Immunity, Herd | 1 | 2006 | 2 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3030 | 0.020 |
Why?
|
| Point Mutation | 1 | 2006 | 246 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 154 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 819 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 1851 | 0.010 |
Why?
|